Lupus Nephritis

Why Lupus nephritis class IV is correct

• Full-house immunofluorescence (IgG, IgM, IgA, C3, C1q) is characteristic of lupus nephritis.
• Positive anti-double-stranded DNA with low C3 and C4 indicates active systemic lupus erythematosus with immune-complex consumption.
• Endocapillary proliferation involving 50% or more of glomeruli, typically with subendothelial immune deposits, defines diffuse lupus nephritis (ISN/RPS class IV); 80% of glomeruli are involved here.
• Diffuse proliferative (class IV) is the most common and most severe class; the active sediment (RBC casts, heavy proteinuria) and elevated creatinine fit it.

Why the others are wrong

• Membranoproliferative glomerulonephritis type I - also lowers complement (buzzword trap), but lacks full-house immunofluorescence and is not associated with anti-double-stranded DNA or lupus serologies.
• Lupus nephritis class V - membranous lupus nephritis is defined by subepithelial deposits with glomerular basement membrane thickening and usually presents as nephrotic syndrome with a relatively bland sediment; pure class V lacks the endocapillary proliferation and subendothelial deposits seen here and seldom produces red cell casts.
• Post-streptococcal glomerulonephritis - depresses C3 (not typically C4), follows a streptococcal infection, and lacks anti-double-stranded DNA and full-house staining (anchoring on low complement).
• Lupus nephritis class III - focal lupus nephritis can show the same endocapillary proliferation and subendothelial deposits, but by ISN/RPS definition it involves fewer than 50% of glomeruli; with 80% involved, this is diffuse disease (focal-versus-diffuse threshold trap).

Why Continue immunosuppression with individualized reassessment for a cautious taper; hydroxychloroquine indefinitely is correct

• After induction, lupus nephritis maintenance with MMF (typically 1–2 g/day) or azathioprine is generally continued for several years before any withdrawal is considered.
• KDIGO and EULAR/ERA support a cautious, individualized taper once complete renal remission has been sustained (often around 3 years), rather than a fixed additional course for everyone.
• This patient already has 3 years of complete remission, so the decision now is whether to begin a gradual, closely monitored taper — not to reset the clock with another fixed multi-year course.
• Renal flare risk after withdrawal is meaningful, so tapering should be slow and paired with ongoing surveillance of proteinuria, serologies, and eGFR.
• Hydroxychloroquine is continued indefinitely in all SLE patients: it reduces flares, damage accrual, cardiovascular events, and thrombosis.

Why the others are wrong

• Taper off all immunosuppression after 1 year of sustained remission; discontinue hydroxychloroquine — Right concept (eventual taper) but wrong timing; one year of remission is too brief and premature withdrawal carries a substantial flare risk. Stopping hydroxychloroquine also raises the risk of flares and damage accrual; it is continued indefinitely unless toxicity develops.
• Replace mycophenolate with belimumab for long-term maintenance; continue hydroxychloroquine indefinitely — The hydroxychloroquine plan is right, but belimumab is approved for lupus nephritis only as an add-on to standard immunosuppression (mycophenolate, or cyclophosphamide followed by azathioprine); substituting it for mycophenolate abandons proven maintenance therapy and is not endorsed by KDIGO or EULAR.
• Switch to low-dose prednisone monotherapy for long-term maintenance; discontinue hydroxychloroquine — Confused-with adequate maintenance; steroid monotherapy lacks disease-modifying benefit and adds cumulative steroid toxicity, so it does not replace MMF or azathioprine. Stopping hydroxychloroquine also forfeits its protection against flares, damage accrual, and thrombosis.
• Switch to quarterly intravenous cyclophosphamide pulses for maintenance; continue hydroxychloroquine indefinitely — this was the maintenance phase of the original NIH protocols, but mycophenolate or azathioprine replaced it after trials showed fewer infections and less amenorrhea with comparable or better renal outcomes; adding cumulative cyclophosphamide exposure in a patient in sustained remission on MMF only adds gonadal, infectious, and malignancy risk.

Additional high-yield points

• Factors favoring longer maintenance before taper: persistent low-level proteinuria, elevated anti-dsDNA, low complement, African-American ethnicity, multiple prior flares.
• Hydroxychloroquine monitoring: annual ophthalmologic screening for retinal toxicity after 5 years of use.
• ACE inhibitors should be continued indefinitely for BP control and antiproteinuric effect.